AR060592A1 - Mab anti - igf- ir fucosilado - Google Patents

Mab anti - igf- ir fucosilado

Info

Publication number
AR060592A1
AR060592A1 ARP070101538A ARP070101538A AR060592A1 AR 060592 A1 AR060592 A1 AR 060592A1 AR P070101538 A ARP070101538 A AR P070101538A AR P070101538 A ARP070101538 A AR P070101538A AR 060592 A1 AR060592 A1 AR 060592A1
Authority
AR
Argentina
Prior art keywords
igf
fucosilado
amount
mab anti
antibody
Prior art date
Application number
ARP070101538A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36940705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR060592(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR060592A1 publication Critical patent/AR060592A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un anticuerpo que fija sobre el IGF-IR, es del tipo IgG1 o IgG3 humano y está glucosilado con una cadena azucar en asn297, dicho anticuerpo está caracterizado porque la cantidad de fucosa dentro de dicha cadena azucar es por lo menos del 98% y además la cantidad de NGNA es del 1% o menos y/o la cantidad de alfa-1,3-galactosa del extremo N es del 1% o menos, tiene propiedades mejoradas para la terapia anti-tumoral.
ARP070101538A 2006-04-11 2007-04-11 Mab anti - igf- ir fucosilado AR060592A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06007571 2006-04-11

Publications (1)

Publication Number Publication Date
AR060592A1 true AR060592A1 (es) 2008-07-02

Family

ID=36940705

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101538A AR060592A1 (es) 2006-04-11 2007-04-11 Mab anti - igf- ir fucosilado

Country Status (20)

Country Link
US (1) US20080014203A1 (es)
EP (2) EP2363417A1 (es)
JP (1) JP4718634B2 (es)
KR (2) KR101276513B1 (es)
CN (1) CN101421305B (es)
AR (1) AR060592A1 (es)
AU (1) AU2007236199B2 (es)
BR (1) BRPI0710185B8 (es)
CA (2) CA2647181C (es)
CR (1) CR10301A (es)
EC (1) ECSP088816A (es)
ES (1) ES2403075T3 (es)
IL (1) IL194397A (es)
MX (1) MX2008012950A (es)
NO (1) NO20084082L (es)
NZ (1) NZ571414A (es)
RU (1) RU2541765C2 (es)
UA (1) UA95284C2 (es)
WO (1) WO2007115814A2 (es)
ZA (1) ZA200808597B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7846724B2 (en) * 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
WO2008079849A2 (en) * 2006-12-22 2008-07-03 Genentech, Inc. Antibodies to insulin-like growth factor receptor
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
JP5458020B2 (ja) 2007-12-21 2014-04-02 ロシュ グリクアート アクチェンゲゼルシャフト 抗体の安定性試験
PT2376116E (pt) 2008-12-12 2016-02-24 Boehringer Ingelheim Int Anticorpos anti-igf
WO2010112194A1 (en) * 2009-04-02 2010-10-07 F. Hoffmann-La Roche Ag Antigen-binding polypeptides and multispecific antibodies comprising them
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
ES2478294T5 (es) 2009-07-24 2024-08-02 Hoffmann La Roche Sistema de agitador
WO2011044336A2 (en) * 2009-10-07 2011-04-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human domain antibodies against components of the human insulin-like growth factor (igf) system
BR112012009828B8 (pt) 2009-10-26 2022-10-25 Hoffmann La Roche Método para a produção de uma imunoglobulina glicosilada e seu uso
WO2011101328A2 (en) 2010-02-18 2011-08-25 Roche Glycart Ag Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor
WO2011135040A1 (en) 2010-04-30 2011-11-03 F. Hoffmann-La Roche Ag Fluorescent antibody fusion protein, its production and use
CA2815282C (en) 2010-11-05 2019-05-21 F. Hoffmann-La Roche Ag Optimized method for antibody capturing by mixed mode chromatography
ES2667864T3 (es) 2011-06-22 2018-05-14 F. Hoffmann-La Roche Ag Eliminación de células diana mediante linfocitos T citotóxicos específicos de virus en circulación usando complejos que comprenden MHC de clase I
RU2502798C2 (ru) * 2012-02-22 2013-12-27 Общество с ограниченной ответственностью "Фармако Биотех" КЛЕТОЧНАЯ ЛИНИЯ huFSHIK, СЕКРЕТИРУЮЩАЯ РЕКОМБИНАНТНЫЙ ЧЕЛОВЕЧЕСКИЙ ФСГ
EP2727941A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Method for the production of multispecific antibodies
US20150259430A1 (en) 2012-11-05 2015-09-17 Mab Discovery Gmbh Method for the production of multispecific antibodies
MX361076B (es) 2012-12-21 2018-11-27 Hoffmann La Roche Proteínas multifunción que comprenden complejo mayor de histocompatibilidad (cmh) de clase i multivalente unido mediante disulfuro.
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
AR120719A1 (es) * 2019-12-10 2022-03-09 Horizon Therapeutics Ireland Designated Activity Company Anticuerpos glicosilados contra el receptor del factor de crecimiento i similar a la insulina y sus usos

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US5202238A (en) * 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) * 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
US5610297A (en) * 1991-12-27 1997-03-11 Georgia Tech Research Corp. Peptides ketoamides
DK0669836T3 (da) 1992-11-13 1996-10-14 Idec Pharma Corp Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom
DK1914244T3 (da) * 1999-04-09 2013-07-22 Kyowa Hakko Kirin Co Ltd Fremgangsmåde til at modulere aktiviteten af funktionelle immunmolekyler.
US20030165502A1 (en) * 2000-06-13 2003-09-04 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
US7553485B2 (en) * 2002-01-18 2009-06-30 Pierre Fabre Medicament Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
EP2316921B1 (en) * 2002-05-24 2014-05-14 Merck Sharp & Dohme Corp. Neutralizing human anti-IGFR antibody
CA2519113C (en) * 2003-04-02 2012-06-05 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
US7579157B2 (en) * 2003-07-10 2009-08-25 Hoffmann-La Roche Inc. Antibody selection method against IGF-IR
WO2005014651A1 (ja) * 2003-08-11 2005-02-17 Chugai Seiyaku Kabushiki Kaisha 糖鎖改変抗hm1.24抗体
JP4794303B2 (ja) * 2003-10-10 2011-10-19 中外製薬株式会社 固形腫瘍治療剤

Also Published As

Publication number Publication date
CA2647181A1 (en) 2007-10-18
RU2008144290A (ru) 2010-05-20
ECSP088816A (es) 2008-11-27
EP2007810B1 (en) 2013-02-13
RU2541765C2 (ru) 2015-02-20
IL194397A (en) 2014-04-30
BRPI0710185B1 (pt) 2020-01-14
BRPI0710185A2 (pt) 2011-08-09
UA95284C2 (ru) 2011-07-25
US20080014203A1 (en) 2008-01-17
JP2009533367A (ja) 2009-09-17
JP4718634B2 (ja) 2011-07-06
BRPI0710185B8 (pt) 2021-05-25
WO2007115814A2 (en) 2007-10-18
CN101421305A (zh) 2009-04-29
WO2007115814A3 (en) 2008-01-10
BRPI0710185A8 (pt) 2019-01-22
AU2007236199A1 (en) 2007-10-18
NZ571414A (en) 2011-12-22
EP2007810A2 (en) 2008-12-31
ZA200808597B (en) 2009-11-25
MX2008012950A (es) 2008-10-15
CR10301A (es) 2008-10-29
AU2007236199B2 (en) 2013-07-25
KR20080113233A (ko) 2008-12-29
NO20084082L (no) 2008-11-06
KR101276513B1 (ko) 2013-06-21
ES2403075T3 (es) 2013-05-13
CA3081707A1 (en) 2007-10-18
CA2647181C (en) 2020-08-11
EP2363417A1 (en) 2011-09-07
CN101421305B (zh) 2013-05-15
KR20120028396A (ko) 2012-03-22
IL194397A0 (en) 2011-08-01

Similar Documents

Publication Publication Date Title
AR060592A1 (es) Mab anti - igf- ir fucosilado
ECSP088814A (es) Anticuerpos fucosilados
CL2008003788A1 (es) Composicion farmaceutico que comprende a) el anticuerpo b-ly1 humanizado (anti-cd20/antigeno de referenciacion restringida del linfocito b humano/bp35, de tipo ii), b) opcionalmente de 0,001% al 1%p/v de por lo menos un surfactante, y c) de 1 a 100 mm de un tampon; uso para tratar enfermedades relacionadas con cd20.
CL2007003726A1 (es) Anticuerpos anti-receptor del factor del crecimiento similar a la insulina i (igf-ir); composicion farmaceutica que lo contiene; y su uso para tratar el cancer.
CL2007002667A1 (es) Uso de trastuzumab para la prevencion o reduccion de la metastasis en un paciente que padece de cancer her2 positivo, que no responde a una monoterapia con trastuzumab ni a una monoterapia con pertuzumab.
CL2012000518A1 (es) Uso de un anticuerpo aislado o fragmento de enlace antígeno del mismo que comprende una región variable de cadena ligera y una de cadena pesada (sec nº38 y nº40) útil en el tratamiento y prevención de mieloma en un mamífero (div. sol. 3615-07).
PA8782201A1 (es) Anticuerpo humanizados contra el globulómero ab(20-42) y sus usos
CL2007001724A1 (es) Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
MX358013B (es) Materiales y metodos para el tratamiento o prevencion de enfermedades asociadas al her-3.
PE20081899A1 (es) Anticuerpos anti-ige
EP1847602A4 (en) STABILIZED HUMAN IGG1 AND IGG3 ANTIBODIES
CL2007002594A1 (es) Compuestos derivados de piridin-3-il, agentes inmunomoduladores; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades asociadas con un sistema inmunologico activado. .
EA200870132A1 (ru) Антитела против cd19 с пониженной иммуногенностью
BRPI0717845A2 (pt) Uso de compostos, composições farmacêuticas e métodos para o tratamento e/ou profilaxia de enfermidades que podem ser tratadas com agentes de elevação de colesterol-hdl e compostos
CL2006003672A1 (es) Compuestos derivados de pirimido-[4,5-b]-oxazinas; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de diabetes mellitus y/u obesidad.
AR057239A1 (es) Inmunoglobulinas
CL2008000303A1 (es) Compuestos derivados de 1-oxa-3-azaespiro[4.5]decan-2-ona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de un trastorno de la alimentacion, obesidad, depresion.
CL2008000910A1 (es) Proteina de fusion que comprende una proteina que corta el peptido beta amiloide; composicion farmaceutica que la comprende, y su uso para prevenir y/o tratar enfermedades relacionadas con el peptido beta amiloide.
CR10143A (es) Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos y métodos de uso en la terapia del cáncer
CL2007003825A1 (es) Composicion farmaceutica que comprende un anticuerpo monoclonal humanizado anti-antigeno de diferenciacion leucocitario humano cd6; y su uso para el diagnostico y tratamiento de la leucemia linfocitaria cronica b.
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
HK1102076A1 (en) Recombinant chemokine-antigen vaccine
CL2007000974A1 (es) Anticuerpo monoclonal anti-nectina 2; composicion farmaceutica que lo comprende; y su uso para tratar o prevenir el cancer.
ATE402827T1 (de) Sicherheitselemente mit durch energieeintrag aktivierbaren eigenschaften
UA96426C2 (ru) Выделенное человеческое или гуманизированное антитело, которое специфически связывается с il-13

Legal Events

Date Code Title Description
FG Grant, registration